Six months after Amgen and AstraZeneca reported promising results for Tezspire (tezepelumab) as a potential treatment for chronic obstructive pulmonary disorder (COPD), the companies are touting the ...
Credit: Amgen AstraZeneca Tezspire is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin, an epithelial cytokine involved in the initiation and persistence ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
THOUSAND OAKS, Calif., Nov. 7, 2024 /PRNewswire/ -- Amgen (AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...
In December 2021, the US Food and Drug Administration (FDA) approved Tezspire (tezepelumab-ekko; Amgen, Inc and AstraZeneca AB), a thymic stromal lymphopoietin (TSLP) blocker, for the add-on ...
Aiolos Bio launched with a $245 million series A investment to advance its novel, Phase 2-ready antibody for treating asthma, the firm said earlier this week. The biotech startup is aiming to best ...
WILMINGTON, Del.--(BUSINESS WIRE)--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of ...
Dublin, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The "TEZSPIRE Market Size, Insight, and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive ...
Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (AZN) and Amgen’s TEZSPIRE® (tezepelumab ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen’s TEZSPIRE (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years ...
THOUSAND OAKS, Calif., Feb. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for ...
The US Food and Drug Administration (FDA) has approved tezepelumab-ekko (Tezspire) as a first in class treatment for severe asthma in adults and pediatric patients aged 12 years and older. It is not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results